Grace Therapeutics IncGRCE
Price$2.04

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$20.2MTTM through 30 Jun 2026
Free Cash Flow -$10.3MTTM through 30 Jun 2026

Margins

Current

Returns

-12.2%ROE
-11.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio8.10x
Net Debt-$17Mnet cash position
Cash & Equivalents$13.8M

Quality Metrics

Altman Z-Score6.41
Piotroski F-Score2 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'22
FY2022: $100M
Diluted EPS-$1.17TTM
'22'23'24'25'26
FY2026: $-0.47

Dividend

No dividend

Capital Allocation

R&D Spend$2.1M

Segment Performance

SegmentRevenueYoYOutlook
Pharmaceutical Development$0
View details

Remediation efforts are underway following an April 2026 Complete Response Letter from the FDA regarding the GTx-104 NDA. Internal funding for GTx-102 and GTx-101 was halted in June 2026 to prioritize GTx-104.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.